4-hydroxy-3-[2-(4-phenylphenyl)-3,4-dihydro-2H-chromen-4-yl]chromen-2-one | 56073-18-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: 4-hydroxy-3-[2-(4-phenylphenyl)-3,4-dihydro-2H-chromen-4-yl]chromen-2-one
• CAS: 56073-18-8
• 化学式: C₃₀H₂₂O₄
• 分子量: 446.502
• InChiKey: FMUGUAKWPMKECV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  34
• 可旋转键数：
  3
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-hydroxy-3-[2-(4-phenylphenyl)-3,4-dihydro-2H-chromen-4-yl]chromen-2-one 在 三氯化铝 作用下， 反应 0.5h， 生成 13-(4-Phenylphenyl)-4,12,14-trioxapentacyclo[11.7.1.0^{2,11}.0^{5,10}.0^{15,20}]henicosa-2(11),5,7,9,15(20),16,18-heptaen-3-one
  参考文献：
  名称：

  Design and synthesis of novel diphenacoum-derived, conformation-restricted vitamin K 2,3-epoxide reductase inhibitors

  摘要：

  Two novel diphenacoum-derived analogues 5 and 6 are designed, synthesized and tested as potential vitamin K 2,3-epoxide reductase (VKOR) inhibitors. The inhibition studies indicated that 5 is a potent VKOR inhibitor, which confirmed that the replacement of the tetrahydronaphthalene on diphenacoum to a chroman functionality does not have a major impact on inhibition potency. The conformation-restricted compound 6 is a moderate inhibitor which may serve as a lead compound for further study of the mode of action of coumarin-type anticoagulants at the molecular level. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.03.005
• 作为产物：
  描述：

  2-([1,1′-biphenyl]-4-yl)chroman-4-one 在 sodium tetrahydroborate 、 对甲苯磺酸 作用下， 以 甲醇 、 1,2-二氯乙烷 为溶剂， 反应 6.5h， 生成 4-hydroxy-3-[2-(4-phenylphenyl)-3,4-dihydro-2H-chromen-4-yl]chromen-2-one
  参考文献：
  名称：

  Design and synthesis of novel diphenacoum-derived, conformation-restricted vitamin K 2,3-epoxide reductase inhibitors

  摘要：

  Two novel diphenacoum-derived analogues 5 and 6 are designed, synthesized and tested as potential vitamin K 2,3-epoxide reductase (VKOR) inhibitors. The inhibition studies indicated that 5 is a potent VKOR inhibitor, which confirmed that the replacement of the tetrahydronaphthalene on diphenacoum to a chroman functionality does not have a major impact on inhibition potency. The conformation-restricted compound 6 is a moderate inhibitor which may serve as a lead compound for further study of the mode of action of coumarin-type anticoagulants at the molecular level. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.03.005

文献信息

• Design and synthesis of novel diphenacoum-derived, conformation-restricted vitamin K 2,3-epoxide reductase inhibitors
  作者：Ding-Uei Chen、Pei-Yu Kuo、Ding-Yah Yang

  DOI：10.1016/j.bmcl.2005.03.005

  日期：2005.5

  Two novel diphenacoum-derived analogues 5 and 6 are designed, synthesized and tested as potential vitamin K 2,3-epoxide reductase (VKOR) inhibitors. The inhibition studies indicated that 5 is a potent VKOR inhibitor, which confirmed that the replacement of the tetrahydronaphthalene on diphenacoum to a chroman functionality does not have a major impact on inhibition potency. The conformation-restricted compound 6 is a moderate inhibitor which may serve as a lead compound for further study of the mode of action of coumarin-type anticoagulants at the molecular level. (c) 2005 Elsevier Ltd. All rights reserved.